Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Beam Therapeutics

< Previous 1 2 Next >
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Upcoming September Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Tickers BEAM
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.